Manufacturing

Inovio received a $71-million contract from the US Department of Defense to scale up manufacture of its Cellectra smart device to deliver its DNA vaccine.

The facility has dedicated manufacturing and packaging for oral solid dosage forms, liquids, creams, and ointments.

The company will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing capabilities.

The company will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France.

Manufacturers are adapting with virtual work, remote monitoring, and re-evaluation of facility design to ensure worker safety.

New options for pharmaceutical tubes enhance functionality, sustainability, and brand identity.

Cobra Biologics has signed a supply agreement to provide GMP manufacturing for AstraZeneca’s AZD1222 COVID-19 vaccine candidate.

Corning will use BARDA funding to expand US manufacturing capacity for pharmaceutical tubing and vials made from Valor glass.

The company is planning on adding up to 1.5 million sq. ft. of cGMP distribution space for COVID-19 shipments.

Oxford Biomedica, has signed a collaboration agreement with the not-for-profit organization, the Vaccines Manufacturing and Innovation Centre, to provide the UK with its first strategic vaccine development and advanced manufacturing capability.

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.

Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility.

The investment will increase production lines for bulk drug substance and will add a fill/finish production line to the site.

Siemens and Exyte partner for fast-track construction of modular, automated, digitalized biopharmaceutical facilities.

SiO2 Materials Science has received $143 million from the US government to accelerate capacity scale-up of its advanced primary packaging platform.

The VIA Capsule from Cytiva is a liquid nitrogen-free cryogenic shipment system designed to transport cell therapies.

The center will offer expertise in fill-finish optimization and analytical testing.

Achieving herd immunity will require testing, data, a vaccine, and public support.

Advances in intelligent technologies for pharmaceutical packaging improve online productivity, authenticate product, and boost patient adherence.

Consider how to assess risks and understand possible sources of disinfectant residues in pharmaceutical manufacturing.

Advanced analytics streamlines continuous manufacturing by providing improved insights to data.

The global COVID-19 pandemic has highlighted the need for the pharmaceutical industry to strengthen its supply chain.

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.